The Ministry of Health reports the measles vaccination campaign in the country has completed its fourth week and  63% of the vaccines had been administered as of Jan. 11. The country is carrying out...

Earlier this week, Senate Minority Leader, Chuck Schumer of New York made a statement concerning the shortage of the popular shingles vaccine, Shingrix and seemed to link it to the current government...

Biotech company, Valneva announced today the signing of a new $59 million contract with the U.S. government Department of Defense for the supply of its Japanese encephalitis (JE) vaccine IXIARO® . Valneva’s...

The U.S. Food and Drug Administration has approved the expanded use of Adacel® (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccine Adsorbed) to include repeat vaccination...

San Antonio flu activity is on the rise and the San Antonio Metropolitan Health District (Metro Health) wants to help by giving away free flu vaccine. Currently, after a slow start, Metro Health is seeing...

Why is it so challenging to increase the number of people who get vaccinated? How does popular resistance to vaccination remain strong even as preventable diseases make a comeback? A new study from Dartmouth...

Novavax, Inc. announced recently of top-line results of its Phase 2 clinical trial of NanoFlu™. The trial compared the safety and immune responses of various quadrivalent formulations of NanoFlu, with...

Just weeks after announcing the U.S. Food and Drug Administration (FDA) granted Fast Track designation for VLA1553, their Chikungunya vaccine candidate, Valneva announced today positive Phase 1 interim...

Global health care company, Sanofi, announced Wednesday that the US Food and Drug Administration (FDA) approved the pediatric hexavalent combination vaccine, VAXELIS™ . VAXELIS was developed as part...

In a follow-up on Valneva’s Chikungunya vaccine candidate, the France based biotech company announced Friday that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation...